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Effect of nasal continuous positive airway pressure on 
methacholine-induced bronchoconstriction 
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CHIH-TENG Yu, WEN-BIN SHIEH AND HAN-PIN Kuo* 
Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan 
Bronchial hyper-responsiveness is a cardinal feature of asthma. To determine whether nasal continuous 
positive airway pressure (NCPAP) influences airway smooth muscle in response to exogenous stimuli, we 
examined the effect of NCPAP on aerosolized methacholine-induced bronchoconstriction in 16 stable 
asthmatic patients. The dose-response curve for each subject was measured by a log transformation and linear 
regression analysis as well as a formula fitted to the data points to obtain values for a (slope) and b (position). 
The PD,,FEV, significantly increased in patients receiving 8 cmH,O of NCPAP by one doubling dose 
compared with that in patients using sham pressure. NCPAP shifted the dose-response curves to be flatter, 
deviated upwards and to the right. The coefficient a, indicating bronchial reactivity, was significantly lower in 
patients receiving NCPAP. The coefficient b, indicating the bronchial sensitive threshold, was higher after 
applying NCPAP. In contrast, coefficients a and b did not change in subjects with sham pressure. NCPAP also 
significantly enhanced the bronchodilator effect of inhaled salbutamol in response to methacholine-induced 
bronchoconstriction. In summary, we have shown that NCPAP therapy improves bronchial smooth reactivity 
with an increase in PD,,FEV, and a reduction in the bronchial reactivity and bronchial sensitivity. Therefore, 
NCPAP may provide an adjuvant therapy in patients with acute bronchial asthma. 
Introduction present, or it would worsen sleep patterns without 
improving pulmonary function (6). Continuous positive airway pressure (CPAP) is a 
form of spontaneous breathing where positive airway 
pressure is applied throughout the respiratory cycle. 
It has been established in the management of patients 
with acute diffuse lung injury resulting in adult 
respiratory distress syndrome (1) and when applied 
through the nares, it is also the most effective treat- 
ment for patients with obstructive sleep apnoea (2,3). 
In asthmatic subjects, the effectiveness of nasal con- 
tinuous positive airway pressure (NCPAP) is still 
conflicting (4,5). 
CPAP has been shown to reduce the load on the 
inspiratory muscles and, therefore, decrease the work 
of breathing (5) in histamine-induced bronchospasm. 
A recent report also suggests CPAP at either 5 or 
7.5 cmH,O reduces dyspnoea without interference 
with expiratory airflow (4). However, the application 
Bronchial smooth muscle contraction, airway 
oedema, mucus secretion, and airway inflammation 
constitute the pathophysiological features in bron- 
chial asthma and contribute to the development of a 
fundamental defect in asthma, bronchial hyper- 
responsiveness (7). It has been demonstrated that 
bronchial hyper-responsiveness may be related to the 
airway resting tone in patients with bronchial asthma 
(8). Therefore, it is possible that the application of 
continuous positive pressure in the airways may alter 
the resting tone and subsequently the response of 
smooth muscle to stimuli. In the present study, 
NCPAP was applied to stable asthmatic patients in 
whom bronchoconstriction was induced by metha- 
choline to assess whether NCPAP may influence 
bronchial sensitivity and reactivity. 
of NCPAP in patients with nocturnal asthma was 
suggested to be effective only if sleep apnoea was Materials and Methods 
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27 to 65 (a mean of 46.7 * 11.8) years. All subjects 
met the criteria for the definition of asthma by the 
American Thoracic Society (9). There were no other 
pulmonary or systemic disorders or any occupational 
exposure history in these patients. All of them were 
in a clinically steady state without exacerbation of 
asthma or a respiratory tract infection for 8 weeks 
before the study. Their usual maintenance therapy 
included inhaled &agonists on a ‘as required’ basis 
and oral theophylline which was used at least 4 weeks 
before and throughout the study without changing 
the dosage. No subject was taking corticosteroids in 
any form 6 weeks before or during the study. They 
had not used inhaled bronchodilators for 6 h and 
theophylline for 24 h prior to the methacholine 
challenge test. 
METHACHOLINE CHALLENGE 
Forced expiratory volume in 1 s (FEV,) was 
measured by a Spiroanalyzer ST-350R (Fukuda 
Sangyo. Co Ltd.). The best of three reproducible 
values (with a difference within 200 ml or less than 
5%) was used for the calculation. Methacholine in 
phosphate-buffered saline or phosphate-buffered 
saline alone as its buffer solution was delivered by a 
Rosenthal dosimeter (Model PF2A, Laboratory for 
Applied Immunology Inc.) using a 646 DeVilbiss 
nebulizer. Phosphate-buffered solution was inhaled 
first, followed by methacholine solution at increasing 
concentrations of 0.075, 0.15, 0.3, 0.6, 1.25, 2.50, 5.0, 
10 and 25 mg ml _~ ’ at 5 min intervals. Patients 
received five inhalations for each concentration. The 
FEV, was measured 5 min later before inhalation of 
the next concentration. The log dose-response curves 
for methacholine were constructed as the percentage 
changes in FEV, from the baseline (post-buffer) 
value. The cumulative dose of methacholine causing 
a 20% fall in FEV, (PD,,FEV,) was measured by 
linear interpolation. 
DETERMINATION OF THE LEVEL AND DURATION OF 
NCPAP 
Patients were fitted with a suitable nasal mask and 
CPAP was delivered from a flow generator 
(VitalAire, Marietta, U.S.A.) that provided a con- 
tinuous flow of room air throughout the respiratory 
cycle. The pressure was adjusted with threshold 
valves. 
To select a universally acceptable pressure and 
duration of NCPAP for each subject, different levels 
of pressure with variable duration were applied to all 
our patients in a preliminary study 4 weeks earlier. A 
NCPAP level of 8 cmH,O for 10 min was chosen 
since it was tolerated well by all patients. Higher level 
(2 10 cmH,O) or longer duration of NCPAP was 
not tolerated in some patients due to irritation 
and dryness of nasal mucosa. Patients had been 
acclimatized to NCPAP before entering the study. 
PROTOCOL 
On the first visit, all patients received spirometry 
and methacholine challenge tests without NCPAP. 
On the second visit (1 week later), the baseline 
FEV, was assessed first, then NCPAP was applied 
to each subject. The patients were selected ran- 
domly into a study group of nine patients (four men 
and five women) receiving NCPAP of 8 cmH,O and 
seven patients (six men and one woman) served as 
a control group wearing a NCPAP mask without 
applying positive pressure (sham pressure). After 
NCPAP or sham pressure for 10 min, methacholine- 
challenge began. NCPAP or sham pressure was 
only discontinued during inhalation of methacho- 
line solutions and performance of forced expiratory 
manoeuvres to measure FEV,. After completion, all 
patients were given two puffs of metered-dose sal- 
butamol (100 ~g/pufl) to relieve bronchoconstriction 
induced by methacholine. On both visits, the studies 
were carried out at similar times of the day for each 
subject (morning or afternoon). All measurements 
were made with the subjects seated in the upright 
position. 
To determine whether the effect of NCPAP could 
remain constant following the removal of NCPAP to 
measure FEV,, spirometry was performed 30 s, 1, 2, 
3, 4 and 5 min after the removal of NCPAP 
(8 cmH,O, n=6) or sham pressure (n=5). which was 
applied for 10 min after an induction of a similar 
magnitude of bronchoconstriction by methacholine 
(by decreasing FEV, 20%). 
To further investigate the effect of NCPAP on the 
airway smooth muscle in response to bronchodila- 
tors, a decrease in FEV, by 50% of the baseline value 
was induced by methacholine inhalation in six sub- 
jects (three men and three women) on two separate 
occasions (3-5 days apart). On each occasion, after 
completion of an induced bronchoconstriction by 
methacholine, nebulized salbutamol (1 mg in 1.5 ml 
of 0.45% saline) was given and immediately followed 
by the application of either NCPAP (8 cmH,O) or 
sham pressure on each subject for 30 min, except 
when spirometry was measured at 5, 10, 20 and 
30 min after inhalation of salbutamol. 
EXPRESSION OF RESULTS 
Methacholine dose-response curve 
The methacholine concentration expressed on a 
log scale was related to the percentage change in 
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Table I Characteristics of patients and baseline pulmonary function on two visits 
Age 
Baseline FEV, (1) 
Subject no. (Yr) Sex 1st visit 2nd visit 
NCPAP (8 cmH,O) group 
I 
2 
3 
4 
5 
6 
7 
8 
9 
Mean 
SE 
Control (0 cmH,O) group 
10 
11 
12 
13 
14 
15 
16 
M 
3.00 
Mean 
SE 
55 M 1.09 1.38 
34 F 2.50 2.13 
49 F 1.59 1.50 
31 F 2.65 2.81 
35 M 3.57 3.51 
51 M 2.12 2.04 
39 F 1.92 1.58 
65 M 1.43 1.67 
54 F 2.04 2.01 
46.5 2.10 2.07 
4.03 0.24 0.23 
57 M 1.31 1.46 
53 M 3.30 3.31 
47 F 2.13 2.04 
32 M 3.06 3.03 
57 M 1.83 1.81 
55 M 1.40 1.09 
27 
2.71 
46.8 2.29 2.20 
4.69 0.31 0.31 
Abbreviations: NCPAP, nasal continuous positive airway pressure; FEV,, forced expiratory 
volume in 1 s; M, male; F, female. 
FEV, using linear regression analysis. The log- 
concentration of methacholine was plotted on the 
abscissa and the decline of FEV, on the ordinate 
to make a log dose-response curve. The formula 
y =ax + b was derived by the linear regression method. 
The coefficient a represented the slope of the dose- 
response curve and indicated bronchial reactivity 
(10,13), and the coefficient b represented the position 
of the curve and indicated bronchial sensitivity (11). 
The values of ln[Delta Ratio] were obtained from the 
natural-log transformation of the percentage changes 
in PD2,FEV, before and after the application of 
NCPAP or sham pressure. 
Data analysis 
Data were expressed by mean f SEM. The responses 
obtained in the same subject before and after 
NCPAP or sham pressure were compared using a 
Student’s paired t-test. Comparisons between groups 
(NCPAP to sham pressure) were made using an 
unpaired t-test. Mann-Whitney U test was used to 
compare differences in PD*,FEV, between the two 
groups. The Bonferroni correction was applied to 
the results of multiple comparisons. The level of 
statistical significance was chosen at PCO.05. 
Results 
Table 1 gives the age, sex and baseline pulmonary 
function (FEV,) for the studied subjects. For each 
subject, the baseline FEV, was not significantly dif- 
ferent between two visits. Neither was there a differ- 
ence in the baseline FEV, nor in the mean age 
between the NCPAP group and the sham pressure 
group (Table 1). With the application of NCPAP 
(8 cmHzO), the PD,,FEV, increased significantly 
from 2.2 & 1.9 mg ml - ’ before to 3.7 & 2.9 mg ml ’ 
(n=9, P<O.Ol) (Fig. 1). In contrast, PD,,FEV, in 
the sham pressure control group decreased from 
4.41t 60mg ml- ’ before to 2.41L2.3 mg ml- ’ 
(n=7, P>O.20). The natural log of the delta ratio of 
PD,,FEV, was significantly more pronounced in the 
NCPAP group (4.2 & 0.3 mg ml - ‘, n=9, P~0.05) 
compared with that in the sham pressure control 
group ( - 1.4 I+ 1.4 mg ml- ‘, n=7) (Table 2). There 
was no significant difference in the initial PD,,FEV, 
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Fig. I The changes in PD,,FEV, in patients receiving 
NCPAP of (a) 8 cmH,O ( 0, n = 9) or (b) sham pressure ( 0, 
n=7). P<O.Ol compared with baseline. 
between the two groups. Neither did NCPAP or 
sham pressure influence the baseline FEV, before 
methacholine challenge. 
The typical dose-response curves of methacholine 
in the NCPAP group (subject 4) and the sham 
70 
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Log [methacholine (mg ml-‘)1 
a = 9.44 
b = 2.55 
r = 0.999 
J 
0.01 0.1 1 10 
Log [methacholine (mg ml-‘)] 
Fig. 2 Dose-response curves of methacholine for (a) a 
subject with NCPAP (8 cmHzO) (subject 4) and (b) a 
subject with sham pressure (subject 13) before (pre-NCPAP, 
0) or after (post-NCPAP, 0) the application of pressure. 
For definition of abbreviations for n and h. see Table 2. 
pressure control group (subject 13) are demonstrated 
in Fig. 2. With NCPAP, the curves were flatter and 
shifted to the right compared with baseline curves. 
Sham pressure failed to modify the dose-response 
curves. The values for a, indicating slope and bron- 
chial reactivity, in NCPAP subjects were significantly 
lower (16.6 % 2.2) then those before NCPAP 
(23.9 & 2.9) (n=9, BO.05). The coefficient a did not 
show any significant difference after sham pressure 
(Table 2). The values for b, indicating position and 
bronchial sensitivity, were also significantly (n=9, 
P<O.Ol) lower with NCPAP (16.7 f 3.4) then those 
before (26.3 + 5.1). Sham pressure failed to alter the 
coefficient b (Table 2). 
The bronchodilator effect of NCPAP on 
methacholine-induced bronchoconstriction persisted 
for at least 5 min after the removal of NCPAP. The 
improvements in FEV, in NCPAP (8 cmHzO) group, 
compared with that in the sham pressure group, were 
significant at 30 s and 1 min, and persisted until 5 min 
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60 
0 5 10 20 30 
Time (min) 
Fig. 3 The time-course for the bronchodilator effect of 
inhaled salbutamol in asthmatic patients with NCPAP 
@cmH,O, 0 n=6) or sham p&sure (m, n=6) after 
induction of a 50% decrease in FEV, bv methacholine. 
Data are mean f SEM. *P<O.O5; **&d.05- compared with 
corresponding sham pressure controls. 
after removal of NCPAP (by 21.0 * 2.7% vs. 
2.3 zt 4.2%, 24.2 f 4.3% vs. 3.8 I!C 3.1%, 28.5 =k 3.3% 
vs. 3.1 % 5.0%; PcO.05, n=6, n=5, respectively). 
NCPAP also significantly enhanced the broncho- 
dilator effect of salbutamol compared with sham 
pressure, significant at 10 and 20 min after inhalation 
of salbutamol (by 39.8 *4.1% vs. 29.0 & 3.4%, 
43.8 f 3.8% vs. 32.5 I+ 3.4%; P~0.05, n=6, n=6, 
respectively) (Fig. 3). 
In the past, CPAP was often avoided in patients 
with obstructive airways disease to prevent the risk of 
barotrauma and adverse haemodynamic effects. 
However, recent studies showed CPAP might be 
beneficial in acute asthma. Shivaram et al. suggested 
CPAP reduced both respiratory rate and dyspnoea, 
and assisted inspiratory muscles in patients with 
acute asthma (4,lO). Martin et al. also concluded that 
in induced asthma, CPAP reduced the pulmonary 
resistance and the load on inspiratory muscles to 
improve ventilation (5). Little attention has been 
given to the effect of CPAP on the airway functions. 
In the present study, the application of NCPAP in 
patients with methacholine-induced bronchoconstric- 
tion both significantly lowered the PD,,FEV,, and 
altered the dose-response regression lines. Patients 
with a medium level of NCPAP (8 cmH,O) showed 
improvements in airway sensitivity and airway 
reactivity compared to those with sham pressure. 
Since methacholine-induced bronchoconstriction 
may regress either spontaneously or by transient deep 
inspiration (1 l), it is possible that NCPAP-induced 
reversibility may be due to spontaneous regression or 
an effect of deep breathing in repetitive spirometry 
measurement However, the negative response to 
sham pressure does not support this possibility. The 
bronchodilator effect of NCPAP or sham pressure 
was found to remain constant for more than 5 min 
after removal of applied pressure, suggesting that the 
change in the methacholine-induced constrictive 
responses, determined by measuring the changes in 
FEV, within 3 min of removal of applied pressure in 
our subjects, was adequate to represent the effect of 
NCPAP. 
Previous reports have suggested there is a signifi- 
cant relationship between PD,,FEV, and the base- 
line FEV, (8), suggesting that airway hyper-reactivity 
is dependent on the initial airway tone. Therefore, it 
is possible that the improvement in PD,,FEV, by 
NCPAP in the present study is merely due to a 
non-specific bronchodilator effect of NCPAP on 
baseline airway resistance. However, a trivial effect of 
NCPAP on baseline FEV, discounts this possibility 
and indicates that NCPAP provides a protective 
action in airway smooth muscle against spasmogen 
challenge. Another possible mechanism postulated 
by Smith and Marini (12) is that NCPAP reduces 
expiratory airway resistance and avoids airway col- 
lapse by increasing the in&alumina1 pressure, there- 
fore, pneumatically splinting the airways. This could 
explain in part the improvement in PD,,FEV, in our 
study. 
Oreheck et al. (13,14) have suggested that inhala- 
tion dose-response curves should be studied to evalu- 
ate the airway reactivity. The coefficient a indicates 
the slope of the dose-response curve. The lower its 
value, the flatter the slope. The coefficient b is the 
position of the curve. The higher the value, the more 
the curve is displaced to the right (15). Orehek et al. 
supposed that the bronchial sensitivity (position) 
would indicate the intrinsic properties of the smooth 
muscle and the extrinsic stimuli acting on it. The 
bronchial reactivity (slope) represents levels of bron- 
choconstriction due to different drug doses (13). 
Similar suggestions were also reported by Woolcock 
et al. (15-17) and Beaupre and Mato (18). In the 
present study, NCPAP, but not sham pressure, 
elevated both the threshold of bronchial reactivity 
and sensitivity, indicating NCPAP not only offers 
a pneumatic splitting effect on airway smooth 
muscle but also affects the intrinsic properties of 
smooth muscle contraction, at least in response to 
methacholine. 
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It has been demonstrated that stimuli on the 
bronchopulmonary stretch receptors create a vagal 
positive feedback loop for increasing the contractile 
response, defined as ‘reflex bronchoconstriction’. 
This has been documented in human airways (19-2 1) 
and is likely to be enhanced in asthmatic subjects by 
increasing the cholinergic tonic discharge. The 
increase in reflex results in greater bronchial reactiv- 
ity (13). Hoffstein and Slutsky proposed that 
CPAP could stimulate pharyngeal mechano- 
receptors to stiffen the upper airway (22). Some 
investigators also suggested that the use of CPAP 
may stabilize the upper airway and remove the 
chronic irritation to the oropharyngeal area, with 
subsequent elimination of the reflex bronchocon- 
striction (23). Thereby, NCPAP may intervene in the 
reflex responses in the upper airways and decrease 
bronchial reactivity. Stimulation of inhibitory neural 
pathways in airways, such as the non-adrenergic 
non-cholinergic (NANC) pathway has been sug- 
gested to be contributing to the response to CPAP in 
the upper airways (24). 
This study also showed that NCPAP combined 
with /&-agonist inhalation had a more profound 
bronchodilator effect than the &agonist alone in 
pharmacologically-induced bronchoconstriction. Our 
study provided no clue for an enhancement of 
NCPAP effect on the p-adrenoceptor but suggests 
NCPAP can be used as an adjuvant therapy in relief 
of acute bronchoconstriction. Aside from the effect 
on airway function, NCPAP may reduce the load on 
the inspiratory muscles and decrease breathing work 
(5), resulting in improved ventilation function which 
may also contribute to the effects of NCPAP on 
airway function. Whatever the exact mechanism is, 
NCPAP provides a potent inhibitory action against 
increased airway resistance induced by smooth 
muscle constrictors. 
Taken together, we have demonstrated that 
NCPAP may improve airways hyper-responsiveness 
to exogenous spasmogens and increase the efficacy of 
&agonists in relief of bronchoconstriction. Our 
results indicate a potential therapeutic direction for 
the treatment of acute asthmatic attack. 
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